Skip to content

Salivary, plasma metanephrines and anxiety levels in pheochromocytomas

Salivary, plasma meTanephRines and anxiEty levelS in pheochromocytomaS

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
NL-OMON
Registry ID
NL-OMON20291
Enrollment
435
Registered
2015-02-24
Start date
2015-04-01
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pheochromocytoma, paraganglioma, diagnosis, metanephrines

Interventions

Collecting saliva and collecting 20 ml blood. Filling out a anxiety questionnaire

Sponsors

University Medical Center Groningen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients (age > 18 years) with a pheochromocytoma or sympathetic paraganglioma, with elevated plasma metanephrines AND Germline mutation carriers without elevated plasma metanephrines AND Healthy subjects

Exclusion criteria

Exclusion criteria: The need to use medication known to influence plasma metanephrines concentration: tricyclic antidepressants, phenoxybenzamine, MAO-inhibitors, sympathomimetics, cocaine, methyldopa

Design outcomes

Primary

MeasureTime frame
The diagnostic accuracy (sensitivity and specificity) of salivary levels of metanephrines

Secondary

MeasureTime frame
1. To evaluate the self-reported anxiety levels in patients with a PCC/sPGL, in comparison with healthy subjects and germline mutation carriers without elevated plasma metanephrines levels and to correlate the anxiety levels to the plasma metanephrines levels 2. To determine whether position (sitting vs. supine position) influences salivary metanephrines levels. 3. To establish a reference set for plasma and salivary metanephrines in supine position after 30 minutes of rest 4. To compare the ROC curves for the PCC/sPGL patients with the ROC curve of salivary and plasma metanephrines of asymptomatic germline mutation carriers.

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)